Welcome to our dedicated page for Longeveron news (Ticker: LGVNR), a resource for investors and traders seeking the latest updates and insights on Longeveron stock.
Longeveron Inc. (LGVNR) generates news as a clinical stage biotechnology company developing regenerative medicines based on its lead mesenchymal stem cell therapy, laromestrocel (Lomecel-B). Company announcements frequently focus on progress in clinical trials, new scientific data, intellectual property developments, and participation in major medical and industry forums.
Recent news highlights include updates on the pivotal Phase 2b ELPIS II trial evaluating laromestrocel as a potential adjunct treatment for hypoplastic left heart syndrome (HLHS), a rare pediatric congenital heart defect. Longeveron also reports on its Alzheimer’s disease program, including Phase 2 data from the CLEAR MIND trial showing MRI biomarker evidence of reduced neuroinflammation and associations with preserved brain volume and clinical outcomes in mild Alzheimer’s disease.
Investors and observers can also see coverage of patents granted in the United States and Canada for methods of using Longeveron’s proprietary mesenchymal stem cells to treat aging-related frailty with inflammaging, non-ischemic dilated cardiomyopathy, and female sexual dysfunction. Additional news items describe FDA regulatory milestones, such as designations for laromestrocel in HLHS and Alzheimer’s disease, and acceptance of an IND for Pediatric Dilated Cardiomyopathy.
This page aggregates company press releases and third-party coverage related to Longeveron’s clinical programs, scientific presentations at conferences like CTAD and CVCT, and corporate updates. Users interested in LGVNR stock can review these updates to understand how Longeveron’s stem cell therapy platform is being evaluated across rare pediatric and aging-related conditions.
Longeveron (NASDAQ: LGVN) announced that its Chief Science Officer Dr. Joshua Hare and Chief Medical Officer Dr. Nataliya Agafonova will speak at the Global CardioVascular Clinical Trialists (CVCT) Forum in Washington, D.C., December 8-10, 2025.
The executives will join multiple panel discussions on cell therapy for heart failure, including delivery routes, cell types (mesenchymal stem cell therapy for dilated cardiomyopathy referencing POSEIDON and PATH AHEAD), and multi‑stakeholder debate on streamlining cell therapy innovation while maintaining evidence standards.
Longeveron (NASDAQ: LGVN) announced that the Canadian Intellectual Property Office granted Canadian Patent No. 3043594 covering methods to administer its proprietary mesenchymal stem cell therapy laromestrocel (LOMECEL-B) for treatment of aging-related frailty with inflammaging and for non-ischemic dilated cardiomyopathy (NIDCM).
The patent provides Longeveron with rights in Canada through 2037. The company cites prior Phase 1 and 2 studies that delivered positive initial results in aging-related frailty, including designed improvements in the six-minute walk test and physical functioning. The release emphasizes inflammaging links to frailty and notes MSCs have shown favorable changes in immunologic markers in vivo.
Longeveron (NASDAQ: LGVN) presented Phase 2 CLEAR MIND MRI biomarker data at CTAD 2025 showing that laromestrocel treatment was associated with reduced MRI-measured neuroinflammation (free water) versus placebo across multiple brain regions, most notably the hippocampus and temporal lobe.
Key trial signals include hippocampal free water reductions with dose response (Group 4: p=0.004, N=8; Group 3: p=0.037, N=8), additional regional p-values at week 39, correlated hippocampal volume preservation, clinical benefit, and prior RMAT and fast-track designations from FDA.
Longeveron (NASDAQ: LGVN) announced its submission titled “Reduced brain neuroinflammation after laromestrocel treatment in mild AD: results from the CLEAR MIND study” was selected for a poster at the 18th Clinical Trials on Alzheimer’s Disease Conference (CTAD 2025), held Dec 1–4, 2025 in San Diego.
The poster appears in Poster Session 1 (Section 11: New Therapies and Clinical Trials) with scheduled viewing from Dec 1, 3:00 p.m. PT to Dec 2, 5:30 p.m. PT. The announcement summarizes laromestrocel (Lomecel-B) as a mesenchymal stem cell product proposed to have immunomodulatory and regenerative mechanisms relevant to Alzheimer’s research.
Longeveron (NASDAQ: LGVN) announced the U.S. Patent and Trademark Office granted U.S. Patent No. 12,465,620 for a method of treating aging-related frailty with inflammaging using human mesenchymal stem cells. The patent provides U.S. rights through 2038, with potential for patent-term or regulatory exclusivity extensions.
The company’s lead MSC therapy, laromestrocel, has delivered positive initial results across two clinical trials and prior Phase 1 and 2 studies were designed to show improvements in the six-minute walk test and physical functioning in aging-related frailty patients. Aging-related frailty is described as a multisystem syndrome linked to inflammaging.
Longeveron (NASDAQ: LGVN) reported Q3 2025 results and a business update on Nov 4, 2025. Key clinical milestones include a fully enrolled pivotal Phase 2b trial ELPIS II for laromestrocel in Hypoplastic Left Heart Syndrome (HLHS) with top-line results expected in Q3 2026 and a potential BLA submission in 2027 if results support efficacy. Laromestrocel has multiple regulatory designations for HLHS and Alzheimer’s disease and an FDA‑accepted IND for pediatric dilated cardiomyopathy with a planned pivotal Phase 2 in 2026, subject to financing.
Q3 financials: nine‑month revenue down to $0.8M, net loss $17.3M, and cash of $9.2M as of Sep 30, 2025; cash runway guided into late Q1 2026 with ATM access and prior August financing.
Longeveron (NASDAQ: LGVN) will report third quarter 2025 financial results and provide a business update on Tuesday, November 4, 2025 after U.S. markets close. The company will host a conference call and webcast the same day at 4:30 p.m. ET. Dial-in: 1.877.407.0789 with Conference ID 13755997. A replay of the webcast will be available in the Events & Presentations section of the company website following the call.
Longeveron (NASDAQ: LGVN) announced that Co‑founder and Chief Science Officer Dr. Joshua Hare was interviewed on NPR’s BioTech Nation about hypoplastic left heart syndrome (HLHS) and Longeveron’s investigational stem cell therapy, laromestrocel. The company said its pivotal Phase 2b trial ELPIS II is fully enrolled and top‑line results are anticipated in Q3 2026. ELPIS II follows ELPIS I, where treated children experienced 100% transplant‑free survival to five years versus an approximate 20% mortality rate from historical controls. The trial is conducted with NHLBI via NIH grants. The FDA previously designated laromestrocel as Orphan Drug, Fast Track, and Rare Pediatric Disease, and in August 2024 confirmed ELPIS II as a pivotal trial that could support a BLA if efficacy is demonstrated.
Longeveron (NASDAQ: LGVN) will participate in the 4th Annual ROTH Healthcare Opportunities Conference on October 9, 2025 in New York.
Management will hold one-on-one investor meetings during the conference to discuss the company's clinical-stage cellular therapy programs for rare pediatric and aging-related conditions.
Longeveron (NASDAQ: LGVN), a clinical stage biotechnology company, has appointed Dr. George Paletta, Jr. to its Board of Directors. Dr. Paletta brings extensive experience as an orthopedic surgeon, entrepreneur, and investor, having participated in ASC deals totaling nearly $1 billion.
Dr. Paletta joins Longeveron at a crucial time as the company advances its stem cell therapy pipeline, including a fully enrolled pivotal clinical trial in HLHS with data expected in 2026. The company focuses on developing cellular therapies for life-threatening rare pediatric and chronic aging-related conditions.
As the St. Louis Cardinals' head team doctor, Dr. Paletta holds multiple patents in orthopedic and cardiovascular fields and has founded Preston Worldwide, a medical device company. He completed his medical education at Johns Hopkins and holds an MBA from Washington University's Olin School of Business.